The pathophysiological downside of this regulation may occur in diseases such as chronic kidney disease, where PTH and FGF23 are chronically elevated due to decreased renal 1,25(OH)2D production and phosphate retention. The gene discussed is PTH; the disease is chronic kidney disease.